Progyny Inc. (PGNY)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Seeking Clues to Progyny (PGNY) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Progyny (PGNY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Progyny, Inc. (PGNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Progyny, Inc. (PGNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Progyny, Inc. (PGNY) Soars to 52-Week High, Time to Cash Out?
Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Progyny, Inc. (PGNY) Hits Fresh High: Is There Still Room to Run?
Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Progyny (PGNY) Upgraded to Buy: Here's What You Should Know
Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Progyny (PGNY) a Solid Growth Stock? 3 Reasons to Think "Yes"
Progyny (PGNY) possesses solid growth attributes, which could help it handily outperform the market.
Progyny: Growth Has Returned (Rating Upgrade)
Progyny (PGNY) surges after strong Q3 earnings, robust client growth, and a $200M share buyback, signaling renewed momentum and market confidence. PGNY overcame Amazon's departure by adding new clients, achieving near 100% renewal rates, and accelerating revenue growth across both business segments. Analyst upgrades, insider buying, and secular tailwinds—like rising infertility and delayed childbirth—support a bullish outlook and reinforce the company's competitive moat.
Does Progyny Stock Lead The Pack?
Progyny is a leader in fertility benefits, offering employers comprehensive, outcomes-based solutions that improve treatment success and manage costs. Its focused model has driven strong demand and set it apart in a niche that's expanding quickly within the healthcare sector.
Progyny, Inc. (PGNY) Hit a 52 Week High, Can the Run Continue?
Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
PGNY vs. HQY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Progyny (PGNY) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?
Progyny, Inc. (PGNY) Q3 2025 Earnings Call Transcript
Progyny, Inc. ( PGNY ) Q3 2025 Earnings Call November 6, 2025 4:45 PM EST Company Participants James Hart - Vice President of Investor Relations Peter Anevski - CEO & Director Mark Livingston - Chief Financial Officer Michael Sturmer - President Conference Call Participants Jailendra Singh - Truist Securities, Inc., Research Division Brian Tanquilut - Jefferies LLC, Research Division Michael Cherny - Leerink Partners LLC, Research Division Scott Schoenhaus - KeyBanc Capital Markets Inc., Research Division Nisala Devanath Weerasuriya - BofA Securities, Research Division David Larsen - BTIG, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Progyny, Inc. Earnings Conference Call. [Operator Instructions] I'd now like to turn the call over to your host, James Hart.
Progyny, Inc. (PGNY) Q2 2025 Earnings Call Transcript
Progyny, Inc. (NASDAQ:PGNY ) Q2 2025 Earnings Conference Call August 7, 2025 4:45 PM ET Company Participants James Hart - Vice President of Investor Relations Mark S. Livingston - Chief Financial Officer Michael Sturmer - President Peter Anevski - CEO & Director Conference Call Participants Brian Gil Tanquilut - Jefferies LLC, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division David Michael Larsen - BTIG, LLC, Research Division Jailendra P.
